Diversigen Announces Strategic Partnership With Baylor Miraca Diversigen, Inc. announces a strategic partnership with Baylor Miraca Genetics Laboratories (BMGL), a global leader in genetic testing, to provide their customers access to a broad range of targeted genomics and metabolomics services. The two companies, both commercial endeavors of Baylor College of Medicine, are leveraging the scientific acumen and research infrastructure from the renowned College that founded them. Each company will provide access to the services of the other for customers interested in a greater understanding of the host-microbiome relationship.
Dr. George Gunn joins Diversigen Board of Directors Diversigen, Inc., today announced the appointment of Dr. George Gunn to the company’s Board of Directors. Dr. Gunn is renowned for his successful leadership and contributions to the global animal health and pharmaceutical industries. Until January 2015, Dr. Gunn was Division Head of Novartis Animal Health and a member of the Novartis Executive Committee.
“We believe the name Diversigen encompasses the extensive expertise that we deliver across the entire project life cycle to help our customers understand and harness the vast opportunities rapidly emerging in microbiome research,” according to Joesph F. Petrosino, PhD, Diversigen Founder and Chief Science Officer, as well as Director of the Alkek Center for Metagenomics and Microbiome Research and Associate Professor of Virology and Microbiology at Baylor College of Medicine.
A passionate kiss that lasts more than 10 seconds transfers about 80 million bacteria, researchers say. The evidence, published in the journal Microbiome, comes from 21 couples, ages 17 to 45 who made out for science. Listen to Remco Kort, a microbiologist at the Netherlands Organisation for Applied Scientific Research in Amsterdam and lead author of the study as he speaks with NPR’s Rob Stein in this recent interview. “It is provocative to think that we can perhaps donate beneficial microbes by an ‘oral microbiome transplant,’ ” says Joseph Petrosino, Ph.D., Metanome Founder and Chief Scientific Officer and microbiologist at the Baylor College of Medicine.
Dr. Mills said that he is excited about the opportunity to help lead Metanome to the next level in its development. “Metanome is quickly making a name for itself by partnering with innovative pharmaceutical companies and providing best in class metagenomic services and data analytics, all fueled by access to the breadth and depth of microbiome research at Baylor College of Medicine.”
Metanome scientists Joseph F. Petrosino and Nadim J. Ajami co-author a chapter “Toward the Understanding of the Human Virome”, in this newly published book, which expertly describes the latest metagenomic methodologies and best-practices for microbiome studies from sample collection to data analysis for taxonomic, whole shotgun metagenomic, and metatranscriptomic studies.
Professor Joseph F Petrosino, Chief Scientific Officer at Metanome and Director of the Alkek Center for Metagenomics and Microbiome Research at Baylor College of Medicine, discusses how the Human Microbiome Project aims to characterize the human microbiome and analyze its role in human health and disease.
The positive role of bacteria on the human microbiome – an interview with Professor Joseph F Petrosino, Chief Scientific Officer at Metanome and Director of the Alkek Center for Metagenomics and Microbiome Research at Baylor College of Medicine.
“Metanome, Inc. has been a valuable corporate collaborator in our studies of the human microbiome delivering high-quality, genomic data in a timely manner. I’ve appreciated their responsiveness and willingness to work with Seres Health on meeting our various genomic characterization needs and look forward to continuing to work with Metanome to support our future sequencing efforts.” – Dr. Matthew Henn, Head of Therapeutic Design at Seres Health
Researchers have traveled to the ends of the earth in search of exotic microorganisms that can produce the medicine we need to live and thrive. But as a new study points out, we may have overlooked an extremely rich source of drugs that was right under our noses: bacteria in and on the human body.